Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study.

Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies. PLoS One (2016) 1.52

Patterns of statin initiation and continuation in patients with breast or colorectal cancer, towards end-of-life. Support Care Cancer (2017) 0.75

De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer. Br J Cancer (2016) 0.75

Role of Aspirin in Breast Cancer Survival. Curr Oncol Rep (2017) 0.75

Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer. Br J Cancer (2017) 0.75

Relationship between anti-depressant use and lung cancer survival. Cancer Treat Res Commun (2017) 0.75

Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol (2005) 17.45

Simulation study of confounder-selection strategies. Am J Epidemiol (1993) 12.76

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03

Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol (2001) 7.04

Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol (1986) 6.88

Interpretation and choice of effect measures in epidemiologic analyses. Am J Epidemiol (1987) 6.70

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet (2012) 5.81

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet (2012) 4.85

Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol (1998) 4.73

Aspirin intake and survival after breast cancer. J Clin Oncol (2010) 4.50

Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70

A checklist for medication compliance and persistence studies using retrospective databases. Value Health (2007) 3.64

The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36

Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol (2011) 2.99

The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94

A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed (2007) 2.60

Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst (1996) 2.58

Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol (2012) 2.48

Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res (2006) 2.42

Proper interpretation of non-differential misclassification effects: expectations vs observations. Int J Epidemiol (2005) 2.34

Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med (2013) 2.33

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res (2000) 2.32

Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31

VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell (2012) 2.14

Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am J Epidemiol (2001) 1.87

Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol (2012) 1.85

Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis (2001) 1.67

Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer (2003) 1.55

Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer (2012) 1.54

NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat (2006) 1.50

Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst (2005) 1.50

Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.35

Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat (1996) 1.27

COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat (2011) 1.22

Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol (2010) 1.21

Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest (2012) 1.20

Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol (2003) 1.20

Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2010) 1.20

Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev (2005) 1.20

The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One (2011) 1.14

Increased lymph node metastases at mastectomy for breast cancer associated with host obesity, cigarette smoking, age, and large tumor size. Cancer (1988) 1.14

NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat (2007) 1.12

Screen-detected vs clinical breast cancer: the advantage in the relative risk of lymph node metastases decreases with increasing tumour size. Br J Cancer (2005) 1.07

Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer (2002) 1.07

Factors associated with axillary lymph node metastasis from breast carcinoma: descriptive and predictive analyses. Cancer (1999) 1.07

Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod (2004) 1.06

Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer (2006) 1.04

Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf (2010) 1.04

Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst (2013) 1.02

Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer (2013) 0.99

Effectiveness of organised versus opportunistic mammography screening. Ann Oncol (2009) 0.97

A prospective validated model for predicting axillary node metastases based on 2,000 sentinel node procedures: the role of tumour location [corrected]. Eur J Surg Oncol (2002) 0.90

Anticoagulant medication at time of needle biopsy for breast cancer in relation to risk of lymph node metastasis. Int J Cancer (2013) 0.79